Cardiovascular Disease and Lipoprotein(a) research hub

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

This study offers ongoing treatment with pelacarsen for people who have finished a previous trial for heart disease. It aims to check the long-term safety of the medicine, which helps lower a type of cholesterol called Lp(a).

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD